Diederik van der Reijt of NovaGen Group discusses cellular reprogramming, clinical experience in China and commercialization strategy on theCUBE and New York Stock Exchange Wired: MedTech Unplugged. On theCUBE Research, van der Reijt presents NovaGen Group's platform for epigenetic induction and multipotent stem cell rejuvenation developed from Professor Yi Eve Sun's work. They outline treatment approaches, present clinical data from China and summarize the company's global plans. Gemma Allen of theCUBE Research guides the conversation toward regulatory pathways, clinic openings and cross-border commercialization. Key takeaways include NovaGen Group's reported treatment of approximately 1,000 people with signals of biological age reversal, telomere lengthening and cartilage regeneration according to van der Reijt. They summarize plans for investigational new drug filings and Phase 1/2 trials for amyotrophic lateral sclerosis with breakthrough designation in China and clinic launches in Serbia, Florida and the Middle East. Analysts emphasize artificial intelligence, noting AI's potential to accelerate development and stressing the importance of peer reviewed validation.